Abstract
In vitro activities of cefepime and cefpirome against 96 isolates of Chryseobacterium indologenes and 21 of C. meningosepticum were determined by the agar dilution method. Overall, cefepime was more active than cefpirome against C. indologenes (MIC at which 50% of the isolates were inhibited [MIC50] and MIC90, 4 and 16 microg/ml, respectively, for cefepime and 8 and 128 microg/ml, respectively, for cefpirome). Both agents had poor potency against C. meningosepticum (MIC50 and MIC90, 64 and >256 microg/ml, respectively, for cefepime and 128 and >256 microg/ml, respectively, for cefpirome).
Full Text
The Full Text of this article is available as a PDF (120.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chang J. C., Hsueh P. R., Wu J. J., Ho S. W., Hsieh W. C., Luh K. T. Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother. 1997 Jun;41(6):1301–1306. doi: 10.1128/aac.41.6.1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fuchs P. C., Jones R. N., Barry A. L., Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 May;27(5):679–682. doi: 10.1128/aac.27.5.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hsueh P. R., Hsiue T. R., Hsieh W. C. Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Clin Infect Dis. 1996 May;22(5):858–860. doi: 10.1093/clinids/22.5.858. [DOI] [PubMed] [Google Scholar]
- Hsueh P. R., Hsiue T. R., Wu J. J., Teng L. J., Ho S. W., Hsieh W. C., Luh K. T. Flavobacterium indologenes bacteremia: clinical and microbiological characteristics. Clin Infect Dis. 1996 Sep;23(3):550–555. doi: 10.1093/clinids/23.3.550. [DOI] [PubMed] [Google Scholar]
- Hsueh P. R., Teng L. J., Ho S. W., Hsieh W. C., Luh K. T. Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices. J Clin Microbiol. 1996 Aug;34(8):1908–1913. doi: 10.1128/jcm.34.8.1908-1913.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hsueh P. R., Teng L. J., Yang P. C., Ho S. W., Hsieh W. C., Luh K. T. Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan. Eur J Clin Microbiol Infect Dis. 1997 Aug;16(8):568–574. doi: 10.1007/BF02447918. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Pfaller M. A., Allen S. D., Gerlach E. H., Fuchs P. C., Aldridge K. E. Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):361–364. doi: 10.1016/0732-8893(91)90029-f. [DOI] [PubMed] [Google Scholar]
- Sanders C. C. In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. J Chemother. 1996 Feb;8 (Suppl 2):57–62. [PubMed] [Google Scholar]
- Watanabe N. A. Newer antipseudomonal cephalosporins. J Chemother. 1996 Feb;8 (Suppl 2):48–56. [PubMed] [Google Scholar]